#Denmark #Copenhagen #dermatology #TOOsonix #MikronMed

A New Era in Dermatological Treatment

A transformative partnership between TOOsonix A/S and MikronMed AB is set to make waves in dermatological care across the Nordic region, which boasts a population of about 27 million. This strategic collaboration is aimed at providing patients with rapid and effective treatments for common skin cancers and various skin conditions. Remarkably, many of these treatments can be completed in under 90 seconds.

Innovating Dermatological Care

TOOsonix A/S is recognized as a leader in high-intensity focused ultrasound technology, a cutting-edge approach to dermatological therapy. By teaming up with MikronMed, a distinguished distributor of medical equipment in the Nordic region, TOOsonix is poised to expand the accessibility of its MDR CE marked systems to healthcare professionals throughout the area. MikronMed has been designated as the Authorized Distributor for the Nordic Region by TOOsonix.

The centerpiece of this collaboration is TOOsonix's ONE-M system, an MDR Class IIa CE-marked medical device that utilizes focused ultrasound for dermatological applications. This advanced technology is capable of treating a wide array of conditions such as non-melanoma skin cancers, pre-cancers, and intradermal tumors, and does so without the need for anesthetics or downtime, offering a convenient solution for patients.

A Vision for Widespread Impact

Founders Torsten Bove and Tomasz Zawada from TOOsonix expressed their excitement about the partnership, emphasizing the goal of making focused ultrasound therapy more accessible to patients across the Nordic region. They noted that their non-invasive treatment not only enhances safety but also provides improved aesthetic outcomes compared to traditional methods, positioning it as a valuable option for healthcare providers and patients alike.

MikronMed's CEO, Christer Persson, underscored the potential of TOOsonix’s technology to significantly impact the dermatology market in the Nordic region. With an aging population and an expected 20% of residents over 70 by 2035, there is a rising prevalence of skin cancers and related skin conditions. This collaboration directly addresses the increasing demand for effective, non-invasive dermatological treatments, making it a timely response to the challenges faced in healthcare today.

Addressing a Growing Need

As the incidence of skin cancer escalates, the collaboration between TOOsonix and MikronMed looks to not only meet patient needs but also propel growth in dermatological treatments. The focus on efficient and readily available solutions is a step forward in addressing the healthcare demands of the Nordic populace.

Lone Kunoee, CEO of Consolidated Holdings A/S and chairman of TOOsonix, articulated the broader vision for their partnership, stating that this is merely the beginning of their journey in revolutionizing dermatological care. By forming strategic alliances, the aim is to cater to millions of patients who are in dire need of better therapeutic options.

About TOOsonix A/S

TOOsonix has emerged as a pioneer in high-intensity focused ultrasound technology tailored for dermatological therapy. By collaborating with healthcare professionals across Europe and the U.S., TOOsonix is dedicated to developing innovative treatments for a range of skin conditions, including cancerous, pre-cancerous, and benign growths. For more information, visit www.toosonix.com.

About MikronMed AB

MikronMed specializes in distributing advanced medical devices across various fields including dermatology, ophthalmology, and surgery, and serves the entire Nordic region from its headquarters in Sweden. For further details, visit www.mikronmed.se.